

## **DESMOND JOSEPH FITZGERALD**

### *Early Career*

Following graduation from medical school in University College Dublin, Fitzgerald completed his internal medicine training and a Fellowship in Clinical Pharmacology in Ireland prior to moving to Vanderbilt University. The Department of Clinical Pharmacology at Vanderbilt was world leading in the emerging area of prostaglandin biology and chemistry. He worked in the laboratory of Garret FitzGerald, developing mass spectrometry assays of eicosanoids and aspirin as a means of exploring their role in human disease. He subsequently entered the cardiology-training programme and remained at Vanderbilt as a cardiologist and Director of the Coronary Care Unit at the Veterans Administration Hospital and on the faculty in the Department of Clinical Pharmacology for 5 years.

### *Royal College of Surgeons in Ireland*

On returning to Ireland and after a brief period as an academic consultant in the Mater Misericordiae University Hospital, he was appointed Head of Clinical Pharmacology at the Royal College of Surgeons in Ireland. He grew the department from a handful of staff to over 100 academics, technicians and trainees and established Ireland's first Clinical Research Centre for experimental medicine. He developed a proteomics facility, leading to the establishment of the Centre for Human Proteomics (€15m), a Science Foundation Ireland Centre for Science Engineering and Technology. He established two companies during this time: *SurGen*, a pharmacogenomics programme in partnership with the French genomics company *Genset* and *Java Clinical Research*, a clinical research organisation, which is trading today.

While at RCSI, he was appointed Director of Research responsible for RCSI's major institutional funding bids across all 4 cycles of the Programme for Research in Third Level Institutions. Under the PRTL, RCSI was awarded €42m for series of multidisciplinary and collaborative programmes, including Ireland's first Clinical Research Centre.

### *University College Dublin – Vice President for Research*

In 2004, he moved to UCD as Vice President for Research, motivated by the vision of transforming Ireland's largest university into a world top 100 institution. The university had lagged in research performance behind other national institutions, particularly in competing for funding from the new national agency, Science Foundation Ireland and the EU. Against this backdrop, he worked with a highly committed team to lead the development of research within the university. He was responsible for the university's 7 research institutes, the establishment of university's PhD programmes and for NovaUCD, the university's technology transfer and campus company development programme. He led the university's bids for major national programmes, including 2

cycles of the Programme for Research for Third Level Institutions. During his tenure 2004-2013, UCD's metrics for research improved remarkably, reflected in the QS World Ranking (89<sup>th</sup> in 2009). A special emphasis was placed on the building of large multidisciplinary and multi-partner thematic research programmes across the university and in partnership with other academic institutions and industry, including the National Institute for Bioprocessing Research and Training, INSIGHT (national data analytics centre), the National Digital Research Centre, Food Health Ireland and ICRAIG (National Science Foundation Centre for Geological Sciences). There was a particular focus on EU funding and through a variety of new support measures UCD became the national leader in EU FP7 funding.

*University College Dublin - Vice President for Health Affairs and CAO IEHG*

In 2014, he was appointed Principal of the College of Health Sciences and subsequently Vice-President for Health Affairs and Chief Academic Officer of the Ireland East Hospital Group (IEEHG), a partnership between UCD and its major teaching hospitals. As College Principal, he was responsible for 3 Schools in the College of Health Sciences, namely the School of Medicine and Medical Sciences, the School of Public Health, Physiotherapy and Population Science and the School of Nursing, Midwifery and Health Systems, and for the Penang Medical College in Malaysia. As Chief Academic Officer of the IEHG, he worked alongside the IEHG Executive to develop the governance and management structures underpinning the establishment of the AHSC. During his tenure, UCD health sciences entered the global top 100 for health (Times Higher Education 2015 Subject Rankings). Other key achievements included the establishment of the UCD Precision Medicine Facility, the IEHG Cancer Clinical Academic Directorate, the UCD-SVUH Research Imaging Laboratory, the MMUH-UCD Centre for Innovation in Healthcare and the UCD Beacon Hospital Academy.

**FORMER****OFFICE**

Office of Vice President for Health Affairs,  
UCD Conway Institute,  
University College Dublin,  
Dublin 4, Ireland

**DEGREES**

MB, BAO, BCH (Honours) 1977  
Diploma, Mathematical Statistics (TCD) 1982  
MD (NUI) 1994

**PROFESSIONAL TRAINING**

1980-1983 Registrar in Cardiology, Charitable Infirmary, Dublin.  
1983-1986 Fellow in Clinical Pharmacology and Cardiology, Vanderbilt University.

**Key APPOINTMENTS**

1987-1991 Director, VA Coronary Care Unit, Vanderbilt University  
1994-2004 Chairman, Department of Clinical Pharmacology, RCSI  
2000-2004 Director of Research, RCSI  
2002- 2004 Director of the Institute of Biopharmaceutical Sciences  
Royal College of Surgeons in Ireland  
2004- 2014 Vice-President for Research, University College Dublin  
2014- Principal, College of Health Sciences, UCD  
Chief Academic Officer, Dublin Academic Medical Centre  
2015- Vice-President for Health Affairs, UCD  
Chief Academic Officer, Ireland East Hospital Group

**ACADEMIC APPOINTMENTS**

1989-1991 Associate Professor in Medicine and Pharmacology,  
Vanderbilt University, Nashville  
1991-1994 Consultant Lecturer in Medicine,  
University College Dublin, Ireland  
1994-2004 Professor of Clinical Pharmacology  
Royal College of Surgeons in Ireland  
1996- Adjunct Professor of Medicine, University of Pennsylvania  
2004- Professor of Molecular Medicine, University College Dublin

## **HOSPITAL APPOINTMENTS**

1987-1991	Director, Coronary Care Unit, Veterans Administration Hospital, Nashville
1991-1994	Consultant in Clinical Pharmacology Mater Misericordiae University Hospital, Dublin
1992-2004	Consultant Cardiologist, National Maternity Hospital, Dublin
1994-2004	Consultant Cardiologist, Mater Private Hospital, Dublin
1994-2004	Consultant in Clinical Pharmacology, Beaumont Hospital, Dublin.
2010-	Honorary Consultant in Medicine, St. Vincent's University Hospital

## **PUBLIC APPOINTMENTS (selected)**

1995-2006	Irish Medicines Board
1998-1999	National Technology Foresight Group
1999-2004	Member, Health Research Board
2004-2008	Chairman, Health Research Board
2014-2015	National Genetic & Genomic Medicine Network Strategy Group

## **DIRECTORSHIPS**

SurGen (1999-2003) ( <i>Founder</i> )
JAVA Clinical Research (2001-) ( <i>Founder</i> )
Molecular Medicine Ireland (2003-2011)
National Institute for Bioprocessing Research and Training (2005-2012)
European Cardiovascular Genetics Foundation (2006-2011)
Dublin Academic Medical Centre (2007-)
Dabl Limited (Chairman) (2011-2013)
St. Vincent's University Hospital (2013-2015)
Mater Misericordiae University Hospital (2013-)
Mater Misericordiae and Children's University Hospital Board of Governors (2013-)
Penang Medical College (Malaysia) (2013-)
National Children's Research Centre (2015-)

## **PROFESSIONAL BODIES**

1983-	Member, Royal College of Physicians in Ireland
1989-	Fellow, Royal College of Physicians in Ireland
2000-	Fellow of the European Society of Cardiology
2003-	Fellow of the American Heart Association
2005-	Foreign Member, Association of American Physicians
2017-	Royal Society of Medicine, England

### **EDITORIAL BOARDS (past and current)**

Journal of Cardiovascular Pharmacology

Journal of Thrombosis and Haemostasis

Circulation

International Editorial Board for the European Heart Journal

Cardiovascular Research

Journal of the American College of Cardiology

Biochemical Pharmacology

### **AWARDS**

1984-1986 Merck Sharp and Dohme International Fellowship in Clinical Pharmacology

1986-1988 Pharmaceutical Manufacturers Association Foundation Faculty Development Award

1999 Royal College of Surgeons in Ireland College Medal

2002-2007 Freedom to Discover Award, BMS Foundation

### **COMMITTEES (selected)**

1993-1995 Council, Royal Academy of Medicine in Ireland

1996-2006 Chairman, Clinical Advisory Subcommittee, Irish Medicines Board.

1996-2000 Chairman, Working Group on Platelets and Thrombosis, European Society of Cardiology

1999-2004 Merck Foundation International Fellowships

2000-2005 Bristol Myers Squibb Foundation

2003-2005 Centre for Human Proteomics

2003-2007 Chairman, Health Research Board of Ireland

2003-2006 Physiology & Pharmacology Panel, Wellcome Trust

2011- NHS National Institute Health Research Committee on NIHR Professorships (Deputy Chair)

2014- EU Science Global Challenges Steering Committee

2014- Mater Misericordiae University Hospital QSRM Committee

2015- Ireland East Healthcare Management Executive

2015- Academic Working Group, National Paediatric Hospital Group

### **RESEARCH GRANTS (Selected):**

1988-1993 **NIH-NHLBI HL 40056**  
Coronary Thrombolysis and Platelet Activation \$500,000 (PI)

1988-1993	<b>Veterans Administration</b> VA Merit Award. The Pharmacology of Platelet Inhibition During Coronary Thrombolysis \$500,000 (PI)
1998-2000	<b>Higher Educational Authority PRTL I</b> Biopharmaceutical Sciences Research Resource £350,000 (Lead PI)
1999-2000	<b>Higher Educational Authority PRTL I Cycle 1</b> Institute of Biopharmaceutical Sciences £8.3 million (Lead PI)
2000-2002	<b>Higher Educational Authority PRTL I Cycle 2</b> Biopharmaceutical Sciences Network £11.7 million (Lead PI)
2002-2007	<b>Health Research Board</b> Programme on Cell Regulation by Cyclooxygenases €1.1 milion (Lead PI)
2002-2007	<b>Higher Educational Authority PRTL I Cycle 3<sup>1</sup></b> Programme for Human Genomics €44m (Co-lead PI)
2004-2008	<b>Science Foundation Ireland</b> Regenerative Medicine of Ireland (REMEDI) Proteomics Centre €610,000 (PI)
2004-2008	<b>European Union Framework-6</b> Identification of Risk Genes £8.5m (Proteomics Centre, Co-PI)
2006-	<b>IDA Ireland</b> National Institute of Bioprocessing Research and Training €75m
2007-2012	<b>European Union Framework-7</b> NETSIM Integrated Training Network £5.6m (Co-PI)
2008-2012	<b>Enterprise Ireland</b> Functional Food Centre €11.5m (Co-PI)
2009	<b>City of Dublin Skin and Hospital Trust</b> Charles Institute €12m (PI)
2011-2015	<b>Higher Education Authority PRTL I Cycle5<sup>2</sup></b> Innovation Alliance and UCD Science Centre Phase II €84m (Lead PI)
2013-2016	<b>Science Foundation Ireland</b> International Strategic Collaboration Awards €3.2m (PI)

---

<sup>1</sup> Collaborative programme between RCSI and the Dublin Molecular Medicine Centre (TCD and UCD).

<sup>2</sup> Collaborative programme between TCD and UCD.

## **INVITED LECTURE/MEETING CHAIR (selected)**

Baylor College of Medicine, Visiting Scholar (April 1987)

American Society for Clinical Pharmacology and Therapeutics -Symposium on Restenosis Following Angioplasty and Coronary Thrombolysis (1988)

American Heart Association 61st Sessions - Second International Symposium on Platelet Vascular Occlusion. (November 1988)

American Federation for Clinical Research - Featured Symposium on Thrombolytic Therapy (April 1989)

First Gordon Conference on Thrombolysis - Ventura, California (March 1990)

American Heart Association - Symposium on Coronary Artery Occlusion and Reperfusion, Durango, Colorado. (November 1990)

Second Gordon Conference on Thrombolysis, Ventura, California (March 1992)

Vith World Conference on Clinical Pharmacology, Yokohama, Japan, Organiser - Symposium on Antiplatelet Therapy (June 1992)

American Heart Association, Anaheim, CA (November 1994).

- a. Plenary Session on Unstable Angina
- b. Plenary Session on Fibrinolysis

American Heart Association, Orlando, Florida (November 1997)

Symposium: New Developments in the Prevention of Thrombosis: Lessons from Mice and Men. "Antagonism of GPIIb/IIIa: Current Clinical Status and Future Prospects"

Max-Planck-Institute of Molecular Genetics (May 1998) "Cyclooxygenase: a multifunctional enzyme controlling genes for cell survival"

European Cardiac Society Meeting, Atlanta (August 1998). "The pharmacology of oral glycoprotein IIb/IIIa inhibitors" and "How to stabilise reperfusion: adjunct therapies"

1st European Meeting on Vascular Biology and Medicine Nurnberg (September 1999)  
“Fibrinogen glycoprotein IIb/IIIa interactions in cell signalling”

Japan Pharmaceutical Licensing Association Tokyo, Japan (October 1999) “Development and clinical application of COX-2 inhibitors”

ESC Symposium: Treatment of acute coronary syndrome challenges for the new millennium Sophia Antipolis, France (February 2000). “The role of platelets in UAP”

American College of Cardiology, Anaheim, California (March 2000). New Adjunctive Therapy. “Oral GPIIb/IIIa inhibitors”

EMA Speakers Forum for Aggrastat, Estoril, Portugal (April 2000). “Platelet activation in ACS: implications for acute therapy”

XVth International Congress on Fibrinolysis and Proteolysis, Hamamatsu, Japan (June 2000). “GPIIb/IIIa: basic mechanism and clinical developments”

XXIIInd Congress of the European Society of Cardiology, Amsterdam (August 2000). “Induction of apoptosis in cardiac cells by GPIIb/IIIa antagonists”

European Society of Cardiology Task Force Meeting: Antithrombotic Drugs, Rome (May 2001). “Thienopyridines & GPIIb/IIIa blockers”

4th International Symposium on Platelets & Vascular Occlusion, Capri (May 2001). “Pharmacogenetics in Atherosclerosis”

Symposium: Eicosanoids and Isoeicosanoids: Receptors and Vascular Biology, Paris (July 2001). “Cox-2 inhibitors and the cardiovascular system”

American College of Cardiology, Anaheim, California (March 2000). New Adjunctive Therapy. “Oral GPIIb/IIIa inhibitors”

Winter Eicosanoid Conference Baltimore (March 2001) “Eicosanoids in the Vascular System: Angiogenesis and the Heart”

William Harvey Research Conferences Symposium Nice (October 2001). Progress in the Field of Selective Cox-2 Inhibitors “COX-2 inhibitors and the cardiovascular system”



American Heart Association Symposium, Anaheim, California (November 2001). NSAIDs, Coxibs, and Cardio-Renal Physiology: Clinical Insights, “Cardiovascular Events and Coxibs: What do we know today”?

UK – Japan Platelet Conference, Kyoto (February 2002) “Pharmacogenetics of antiplatelet therapy”

UK Cardiovascular Forum: Developments in Anti-Thrombotic Therapy in Acute Coronary Artery Disease, Seville (June 2002). “Evolving concepts in anti-platelet and anti-thrombotic therapy”

7th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research [ECCR], Frankfurt (October 2002). “Aspirin & cardiovascular prevention – is the evidence in?”

Gordon Conference on Atherosclerosis, New Hampshire (June 2003). “The Proteomics of Platelet Activation”

Atherothrombosis 2003, Florence (June 2003). “Pharmacogenetics of GP11b/111a antagonism”

European Society of Cardiology Congress Vienna (Sept 2003). “Thrombosis in the absence of inflammation”

British Association of Atherosclerosis , Cambridge (Sept 2003). “Platelet Proteomics”

European Society of Cardiology Training Course in Thrombosis, Kiev, Ukraine (Oct 2003). “Pharmacology of Aspirin”

Biosilico, Symposium on Bioinformatics, San Francisco (Nov 2003). “Developments in Proteomics”

American Heart Association Training Programme in Thrombosis, Orlando (Nov 2003). ‘ADP Antagonists’

Symposium ADP Receptors 2004, Bergamo, Italy (May 2004) “Platelet Signalling”

International Society Thrombosis and Haemostasis Standards Committee, Venice (June 2004) ‘Proteomics of Platelets’

American Heart Association Symposium Dallas (Nov 2004). “Antiplatelet Therapy”

Gordon Conference on Platelets and Megakaryocytes. Santa Barbara (March 2005). “Platelet Proteomics”

International Society of Atherosclerosis, Rome (May, 2006). “Role of Platelets in Atherosclerosis”

Hewlett Packard Affiliates Program, San Diego (Oct 2007). “Progress in Biomedical Informatics”

Keystone Meeting on Eicosanoids Big Sky, Montana (Jan 2008). “Proteomics for analysis of biological systems”

ITMAT Symposium on Translational Medicine, Philadelphia (Oct 2009-2015)

National Institute of Health Workshop Remote Monitoring Opportunities and Issues, Washington (June 2010). “Personal Motion Technologies”

International Conference Platelets: Basic Mechanisms and Translational Implications, Tubingen (Oct 2012). “Platelet Proteomics”

Gordon Conference Hemostasis, Waterville NH (July 2014) “Platelet Proteomics Signatures of Drug Response”

International Society of Thrombosis and Haemostasis Toronto (June 2015) State-of-the-Art “Platelet Proteomics”

International School of Pharmacology, Ettore Majorana Foundation Centre for Scientific Culture (EMFCSC), Erice, Sicily (Sept 2015) “Bioactive peptides from bovine milk”

## Publications H index 57

**Fitzgerald DJ**, Gaffney P, Dervan P, Doyle CT, Horgan J, Nelligan M. Giant Lambl's excrescence presenting as a peripheral embolus. *Chest* 81: 516-517, 1982.

O'Boyle CP, McGarry K, **Fitzgerald DJ**, Kelly JG, Horgan J, O'Malley K. Clinical pharmacology of tolmesoxide in refractory heart failure. *Eur. J. Clin. Pharmacol.* 21: 169-172. 1981.

**Fitzgerald DJ**, O'Malley K, O'Brien ET. Inaccuracy of the London School of Hygiene sphygmomanometer. *Brit. Med. J.* 285: 18-19. 1982.

Burke MJ, Towers HM, O'Malley K, **Fitzgerald DJ**, O'Brien ET. Sphygmomanometers in hospital and family practice: problems and recommendations. *Br. Med. J.* 285: 469-471, 1982.

**Fitzgerald DJ**, O'Callaghan W, McQuaid R, O'Malley K, O'Brien ET. Accuracy and reliability of two indirect ambulatory blood pressure recorders: Remler M2,000 and Cardiodyne Sphygmolog. *Br. Heart J.* 48: 472-9, 1982.

**Fitzgerald DJ**, Doyle V, O'Brien ET, Kelly JG, O'Malley K. Beta-adrenoceptor density and responsiveness in borderline hypertension. *J. Hypertension* 1 (Suppl 2): 260-262. 1983.

McGarry K, Laher M, **Fitzgerald DJ**, Horgan J, O'Brien ET, O'Malley K. Baroreflex function in elderly hypertensives. *Hypertension* 5: 763-766. 1983.

**Fitzgerald DJ**, Doyle V, Kelly J and O'Malley K. Cardiac sensitivity to isoprenaline, lymphocyte beta-adrenoreceptors and age. *Clin. Sci* 66: 697-699, 1984.

O'Callaghan WG, **Fitzgerald DJ**, O'Malley K, O'Brien ET. Accuracy of indirect blood pressure measurement in the elderly. *Br. Med. J.* 286, 1545-1546, 1984.

O'Boyle, CB, **Fitzgerald DJ**, Kelly JG, O'Malley K, O'Brien ET. The efficacy of indapamide in hypertensive patients failing to respond to a beta-blocker alone. *Methods Find Exp. Clin. Pharmacol.* 6: 465-9, 1984.

**Fitzgerald DJ**, Roy L, Robertson RM, FitzGerald GA. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in man. *Circulation* 70: 297-302, 1984.

**Fitzgerald DJ**, O'Callaghan W, O'Brien ET, Johnson H, Mulcahy, R., and Hickey N. Home recording of blood pressure in the management of hypertension. *Ir. Med. J.* 78: 216-218, 1985.

**Fitzgerald DJ**, O'Donnell D, Brennan M, O'Malley K, and O'Brien, E. Accuracy and reliability of the Del Mar Avionics Pressormeter. *J. Hypertension* 3: 5359-5361, 1985.

**Fitzgerald DJ**, Doran, J, Jackson E, FitzGerald GA. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation *in vivo*. *J. Clin. Invest.* 27: 496-502, 1986

**Fitzgerald DJ**, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. *N. Engl. J. Med.* 315: 983-989, 1986.

Docherty JR, **Fitzgerald DJ**, O'Malley K. Age related reduction in baroreflex tachycardia without loss of beta adrenoceptor mediated tachycardia in Sprague-Dawley rats. *J. Cardiovasc. Pharmacol.* 8:376-380, 1986.

**Fitzgerald DJ**, Mayo G, Catella F, Entman SS, FitzGerald GA. Increased thromboxane biosynthesis in normal pregnancy largely derives from platelets. *Am. J. Obstetrics Gynecol.* 157: 325-330, 1987.

**Fitzgerald DJ**, Entman SS, Mulloy K, FitzGerald GA. Decreased prostacyclin biosynthesis precedes the clinical manifestations of pregnancy-induced hypertension. *Circulation* 75: 956-963, 1987.

**Fitzgerald DJ**, Catella F, Roy L, FitzGerald GA. Marked platelet activation following intravenous streptokinase in acute myocardial infarction. *Circulation* 77: 142-150, 1988.

**Fitzgerald DJ**, Fragetta J, Fenelon LC, FitzGerald GA. Thromboxane synthase inhibition and thromboxane/endoperoxide antagonism in a chronic canine model of coronary thrombosis. *Adv. Prostaglandin Thromboxane Leukotriene Res.* 17: 496-410, 1987.

Catella F, Lawson JA, **Fitzgerald DJ**, FitzGerald GA. Measurement of multiple enzymatic metabolites of thromboxane B<sub>2</sub> in plasma: a novel approach to the assessment of thromboxane biosynthesis in man. *Adv. Prostaglandin Thromboxane Leukotriene Res.* 17: 611-614, 1987.

O'Brien EO, **Fitzgerald D**, O'Malley K. Comparison of clinic, home and ambulatory blood pressure measurement. *J. Ambulatory Monitoring* 1:285-291, 1988.

**Fitzgerald DJ**, Fragetta J, FitzGerald GA. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. *J. Clin. Invest.* 82:1708-1713, 1988.

O'Brien EO, Cox GP, **Fitzgerald DJ**, O'Malley K. Discrepancy between clinic and ambulatory blood pressure measurements in the evaluation of antihypertensive medications. *J. Human Hypertension* 3: 259-262, 1989.

**Fitzgerald DJ**, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis: Evidence that platelet activation and thromboxane A<sub>2</sub> modulate the response to tissue-type plasminogen activator in vivo. *Circ. Res.* 65: 83-94, 1989.

**Fitzgerald DJ**, FitzGerald GA. Role of thrombin and thromboxane A<sub>2</sub> in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. *Proc. Natl. Acad. Sci.* 86: 7585-7589, 1989.

Kerins DM, Roy L, FitzGerald GA and **Fitzgerald DJ**. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. *Circulation* 80: 1718-1725, 1989.

Takahara K, Murray R, FitzGerald GA, **Fitzgerald DJ**. The response to thromboxane A2 analogues in human platelets: discrimination of two binding sites linked to distinct effector systems. *J Biol Chem* 265: 6836-6844, 1990.

Braden, G., Knapp, H.R., **Fitzgerald, D.J.**, and FitzGerald, G.A.: Dietary fish oil accelerates the response to coronary thrombolysis with tissue-type plasminogen activator: evidence for an antithrombotic effect *in vivo*. *Circulation* 82: 178-187, 1990.

**Fitzgerald DJ**, Rocki W, Catella F, Murray R, Mayo G, FitzGerald GA. Thromboxane A2 biosynthesis in pregnancy-induced hypertension. *Lancet* 335: 751-754, 1990.

Catella F, Lawson J, **Fitzgerald DJ**, FitzGerald GA. Biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. *Proc Natl Acad Sci USA* 87: 5893-5897, 1990.

Catella F, Lawson J, Braden G, **Fitzgerald DJ**, Shipp E, FitzGerald GA. Biosynthesis of P450 products of arachidonic acid in humans: increased formation in cardiovascular disease. *Adv Prost Thromboxane Leuk Res* 21: 193-196, 1990.

FitzGerald GA, Murray R, Moran N, Funk C, Charman W, Clarke R, Furci L, **Fitzgerald D.J.** Mechanisms of eicosanoid action. *Adv Prostagl Thromboxane Leuko Res* 21: 577-582, 1990.

Clarke R, Mayo G, FitzGerald GA, **Fitzgerald DJ**. Combined administration of aspirin and a specific thrombin inhibitor in man. *Circulation* 83:1510-1518, 1991.

Furci L, **Fitzgerald DJ** and FitzGerald GA. Heterogeneity of prostaglandin H2 thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet activation. *J Pharmacol. Exp. Ther.* 258:74-81, 1991.

**Fitzgerald DJ**, Hanson M, FitzGerald GA. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis. *J Clin. Invest.* 88: 1589-1595, 1991.

- Kerins, D., Shuh, M., Kunitada, S., FitzGerald, G.A., and **Fitzgerald, D.J.**: A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: Evidence for a pharmacokinetic interaction. *J Pharmacol Exp Ther* 257:487-492, 1991.
- Kerins DM, Roy L, Kunitada S, Adedoyin A, FitzGerald GA, **Fitzgerald DJ**. Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in man: effect of a prostacyclin analogue. *Circulation* 85: 526-532, 1992.
- Kunitada S, FitzGerald GA, **Fitzgerald DJ**. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. *Blood* 79: 1420-1427, 1992.
- Keimowitz R, **Fitzgerald DJ**. Transdermal modification of platelet function: Selective inhibition of inhibition of platelet cyclooxygenase by aspirin applied to the skin. *Circulation* 88: 556-561, 1993.
- Mc Adam B, Kemowitz R, Maher M, **Fitzgerald DJ**. Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase. *J Pharm Exper Ther* 277: 559-564, 1996.
- Delanty N, Reilly M, Lawson MS, McCarthy JF, Wood AE, **Fitzgerald DJ**, FitzGerald GA. 8-Epi PGF<sub>2</sub> $\alpha$ : generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. *Circulation* 95: 2492-2499, 1997.
- Pratico D, Murphy N, **Fitzgerald DJ**. Interaction of a thrombin inhibitor and a platelet GPIIb/IIIa antagonist in vivo: Evidence that thrombin mediates platelet aggregation and subsequent thromboxane A<sub>2</sub> formation during coronary thrombolysis. *Journal of Pharmacology & Experimental Therapeutics* 281: 1178-1185, 1997.
- O'Brien EC, Le Roy S, Levailain J, **Fitzgerald DJ**, Nolan KB. Metal complexes of salicylhydroxamic acid and O-acetylsalicylhydroxamic acid. *Inorg. Chem. Acta*. 266: 117-120, 1997.

- Byrne A, Moran A, Maher M, Walsh N, Crean P, **Fitzgerald DJ**. Continued thromboxane A<sub>2</sub> formation despite administration of platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. ***Arteriosc. Thromb. Vasc. Biol.*** 17: 3224-3229, 1997.
- Regan CL, McAdam BF, Harhen BM, McParland P, Boylan PC, FitzGerald GA, **Fitzgerald DJ**. Reduced fetal exposure to aspirin using a novel controlled release preparation in normotensive and hypertensive pregnancy. ***Br J. Obs & Gynae.*** 105: 732-738, 1998
- O'Brien EO, Bouchier-Hayes D, **Fitzgerald DJ**, Atkins N, Fennessy F. Towards concentrating on the arterial organ in cardiovascular disease: the ADAPT (Arterial Disease Assessment Prevention and Treatment) Clinic. ***Lancet*** 352: 1700-1702, 1998.
- McMahon GP, O'Connor SJ, **Fitzgerald DJ**, LeRoy S, Kelly MT. Determination of aspirin and salicylic acid in transdermal perfusates. ***J. Chromatography B.*** 707: 322-327, 1998.
- Murphy NP, Pratico D, **Fitzgerald DJ**. Functional relevance of the expression of ligand induced binding sites in the response to platelet GPIIb/IIIa antagonists in vivo. ***J. Pharmacol. Exp. Ther.*** 286: 945-951, 1998.
- Stephens G, O'Luanaigh N, Reilly D, Harriott P, Walker B, **Fitzgerald DJ**, Moran N. A sequence within the cytoplasmic tail of GPIIb independently activates platelet aggregation and thromboxane synthesis. ***J. Biol Chem.*** 273: 20317-20322, 1998.
- Belton OA, Forde R, Lorez HP, **Fitzgerald DJ**. Cyclooxygenase expression in a rat model of focal cerebral ischemia. ***Am Oil Chemists Soc*** 61-63, 1999.
- Cullen L, Kelly L, O'Connor S, **Fitzgerald DJ**. Selective cyclooxygenase-2 inhibition by nimesulide in man. ***J. Pharmacol. Exp. Ther.*** 287: 578-582, 1999.
- Adderley S, **Fitzgerald DJ**. Oxidative damage of cardiomyocytes is limited by *ERK1/2*-mediated induction of cyclooxygenase-2. ***J Biol Chem*** 274: 5038-5048, 1999.



- Quinn M, Deering A, Stewart M, Cox D, Foley B, **Fitzgerald DJ**. Quantifying GPIIb/IIIa receptor binding using two monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists. *Circulation* 99: 2231-2238, 1999.
- Perenby C, Granstrom E, Beck O, **Fitzgerald DJ**, Harhan B, Hjemdahl P. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B<sub>2</sub> in urine: comparison with GC-MS. *Thrombosis Research* 1999; 96: 427-436.
- Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, **Fitzgerald DJ**, Murray FE. The relationship between cyclooxygenase-2 expression and survival in human colorectal cancer. *J. Am Medical Association* 282: 1254-1257,1999.
- Murphy RP, Donoghue C, Nallen RJ, D'Mello M, Regan C, Whitehead AS, **Fitzgerald DJ**. Prospective evaluation of the risk conferred by Factor V Leiden and thermolabile methylene tetrahydrofolate reductase polymorphisms in pregnancy. *Atheroscleros. Thromb. Vasc. Biol.* 20: 266-270, 2000.
- Shah AA, Murray FE, **Fitzgerald DJ**. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. *Rheumatology* 38: 19-23,1999.
- McRedmond JP, Harriott P, Walker B, **Fitzgerald DJ**. Streptokinase-induced platelet activation involves anti-streptokinase antibodies and cleavage of protease-activated receptor-1. *Blood* 95: 1301-1308, 2000.
- Adderley S, **Fitzgerald DJ**. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by Caspase-3 activation. *J. Biol Chem* 275 5760-5766, 2000.
- O'Connor F, **Fitzgerald DJ**, Murphy RP. An automated heteroduplex assay for the P1a polymorphism of glycoprotein IIb/IIIa, multiplexed with two prothrombotic genetic markers, factor V Leiden, and thermolabile methylenetetrahydrofolate reductase. *Thrombosis & Haemostasis* 2000; 83: 248-52.
- Hillman A, Shields D, **Fitzgerald D**, Kenny D. Polymorphisms in glycoprotein Ib alpha are not associated with adverse outcomes in primigravidae. *J Obs Gynaecol* 20: 250-255, 2000.

Moran N, Morateck PA, Deering A, Ryan M, Montgomery R, **Fitzgerald DJ**, Kenny DK. Surface expression of GPIIb $\alpha$  is dependent on GPIIb $\beta$ :- evidence from a novel mutation causing Bernard-Soulier syndrome. ***Blood*** 96: 532-539, 2000.

Belton O, Byrne B, Kearney D, Leahy A, **Fitzgerald DJ**. COX-1 and COX-2 dependent prostacyclin formation in patients with atherosclerosis. ***Circulation*** 102: 840-845, 2000.

O'Brien EC, Farkas E, Gil MJ, **Fitzgerald DJ**, Castineras A, Nolan KB. Metal complexes of salicylhydroxamic acid (H<sub>2</sub>Sha), anthranilic hydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)<sub>2</sub>(Cl)]Cl.H<sub>2</sub>Sha, a model for a peroxidase-inhibitor complex. ***J. Inorg. Biochem.*** 79: 47-51, 2000.

Owens P, Kelly L, Nallen R, Ryan D, **Fitzgerald D**, O'Brien E. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - a randomized controlled trial. ***J Hypertens*** 18: 339-345, 2000.

Topol EJ, Easton JD, Amarenco P, Califf R, Harrington R, Graffagnino C, Davis S, Diener HC, Ferguson J, **Fitzgerald DJ**, Shuaib A, Koudstaal PJ, Theroux P, Van De Werf F, Willerson JT, Chan R, Samuels R, Lison B, Branett J. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. ***Am Heart J*** 139: 927-933. 2000.

O'Neill S, Robinson A, Deering A, Ryan M, **Fitzgerald DJ**, Moran N. The platelet integrin  $\alpha$ IIb $\beta$ 3 has an endogenous thiol isomerase activity. ***J. Biol. Chem.*** 275: 36984-36990, 2000.

Cox, D, Smith R, Quinn M, Theroux P, Crean P, **Fitzgerald DJ**. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. ***J. Am Col. Cardiol.***; 36: 1514-1519, 2000.

O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, **Fitzgerald DJ**. Genetic variation in GPIIb/IIIa as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. ***Blood*** 98: 3256-3260, 2000.

- Hevey D, McGee HM, **Fitzgerald DJ**, Horgan JH. Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients. *Eur. J. Appl. Physiol.* 83: 344-348, 2000.
- Quinn MJ, Cox D, Foley JB, **Fitzgerald DJ**. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. *J Pharmacol Exp Ther* 295: 670-676, 2000.
- Shah AA , Thjodleifsson B,, Murray FE, Sigthorsson G, Gudjonsson H, Oddsson E, **Fitzgerald DJ**, Bjarnason I. Selective inhibition of Cox-2 in man is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. *Gut* 48: 339-346, 2001.
- Quinn MJ, Murphy RT, Dooley M, Foley JB, **Fitzgerald DJ**. Occupancy of the internal and external pools of GPIIb/IIIa following abciximab bolus and infusion. *J. Pharmacol. Exp. Ther.* 297: 496-500, 2001.
- Murphy J, **Fitzgerald DJ**. Vascular endothelial growth factor (VEGF) induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. *The Faseb Journal* 65: 1667-1669, 2001.
- Fullard J, Murphy R, O'Neill S, Moran N, Ottridge B, **Fitzgerald DJ**. A Val 93 Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand. *Br. J. Haematol* 115: 131-139. 2001.
- Dowd NP, Scully M, Adderley SR, Cunningham AJ, **Fitzgerald DJ**. Inhibition of cyclooxygenase-2 (COX-2) aggravates doxorubicin mediated cardiac injury in vivo. *J. Clin. Invest.* 108: 585-590, 2001.
- Loll, PJ, Sharkey C, O'Connor SJ, Dooley CM, O'Brien E, Devocelle M, Nolan KB, **Fitzgerald DJ**. O-Acetylsalicylhydroxamic acid: a novel acetylation inhibitor of prostaglandin H<sub>2</sub> synthase. *Molec. Pharmacol.* 60:1407-1413, 2001.

Stanton A, **Fitzgerald DJ**, Hughes A, Mayet J, O'Brien E, Poulter NR, Sever PS, Shields D, Thom S. An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease. *J. Hum. Hypertens* S13-8, 2001.

Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, **Fitzgerald DJ**, Belton O. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. *J. Pharm. Exp. Ther.* 300: 393-398. 2002.

Kenny D, Muckian C, **Fitzgerald DJ**, Cannon CP, Shields DC. Platelet glycoprotein Iba receptor polymorphisms and recurrent ischaemic events in acute coronary syndromes. *J. Thrombosis and Thrombolysis* 13(1): 13-19, 2002.

Maguire PB, Wynne KJ, Harney DF, O'Donoghue NM, Stephens G, **Fitzgerald DJ**. Identification of the phosphotyrosine proteome from thrombin activated platelets. *Proteomics* 2: 642-648, 2002.

Kerrigan S, Douglas I, Wray A, Heath J, Byrne M, Kenny D, **Fitzgerald DJ**, Cox D. A role for glycoprotein Ib in *Streptococcus sanguis*-induced platelet aggregation. *Blood* 100: 509-516, 2002.

O'Brien L, Kerrigan S, Kaw G, Hogan M, **Fitzgerald DJ**, Foster T, Cox D. *Staphylococcus aureus*-induced platelet aggregation involves clumping factors A and B and the serine-aspartate repeat protein E. *Molecular Microbiology* 2002; 44: 1033-1044.

Muckian C, Fitzgerald A, O'Neill PA, O'Byrne A, **Fitzgerald DJ**, Shields DC. Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. *Blood* 100: 1220-1223, 2002.

Shields DC, Fitzgerald A, O'Neill A, Muckian C, Moran B, Kenny D, Cannon CC, Byrne C, **Fitzgerald DJ**. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. *Pharmacogenomics J* 2(3): 182-190, 2002.

McCrory C, Diviney D, Moriarty J, Luke D, **Fitzgerald D**. Comparison between repeat bolus intrathecal morphine and an epidurally delivered bupivacaine and fentanyl combination in

- the management of post-thoracotomy pain with or without cyclooxygenase inhibition. *J Cardiothorac Vasc Anesth.* 16(5): 607-11, 2002.
- Byrne MF, Corcoran PA, Atherton JC, Sheehan KM, Murray FE, **Fitzgerald DJ**, Murphy JF. Stimulation of adhesion molecule expression by *Helicobacter pylori* and increased neutrophil adhesion to human umbilical vein endothelial cells. *FEBS Lett.* 532(3): 411-414, 2002.
- Quinn MJ, Fullard J, Kerrigan S, Harriott P, Cox D, **Fitzgerald DJ**. Characterization of a ligand-attenuated binding site on glycoprotein IIb/IIIa. *Thrombosis & Haemostasis* 88: 811-816, 2002.
- Dooley CM, Devocelle M, McLoughlin B, Nolan KB, **Fitzgerald DJ**, Sharkey CT. A novel family of hydroxamate based acylating inhibitors of cyclooxygenase. *Molec. Pharm.* 63: 450-455, 2003.
- Devocelle M, McLoughlin BM, Sharkey CT, **Fitzgerald DJ**, Nolan KB. A Convenient parallel synthesis of low molecular weight hydroxamic acids using polymer-supported 1-hydroxybenzotriazole. *Organic & Biomolecular Chemistry* 1: 850-853, 2003.
- Shah AA, Byrne MF, Cullen L, Walsh T, **Fitzgerald DJ**, Murray FE. Effect of *H. pylori* infection on the expression of cyclooxygenase-2 in human gastric mucosa. *Prostaglandins Leukot. Essent. Fatty Acids* 68: 1-8, 2003.
- Byrne MF, Murphy J, Corcoran PA, Atherton JC, Sheehan KM, Cox D, Murray FE, **Fitzgerald DJ**. *Helicobacter pylori* induces cyclooxygenase-1 and cyclooxygenase-2 expression in vascular endothelial cells. *Scand. J. Gastroenterol.* 38(10): 1023-30, 2003.
- VITAL Trial Collaborative Group [**incl DJ Fitzgerald et al**]. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high-risk of dementia. *J. Intern Med* 254: 67-75, 2003.
- Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, **Fitzgerald DJ**, Cox DM. *Helicobacter pylori* binds von Willebrand Factor and interacts with GPIb to induce platelet aggregation. *Gastroenterology* 124: 1846-1854, 2003.

Duffy T, Belton O, Bresnihan B, FitzGerald O, **Fitzgerald DJ**. Inhibition of PGE<sub>2</sub> production by nimesulide compared with Diclofenac in the acutely inflamed joint of patients with arthritis. ***Drugs*** 63 (Suppl 1): 31-36, 2003.

Murphy JF, Steele C, Belton O, **Fitzgerald DJ**. Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of  $\alpha_v\beta_3$ . ***Br. J. Haematol*** 121:157-164, 2003.

Belton OA, Duffy A, Toomey S, **Fitzgerald DJ**. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. ***Circulation*** 108(24): 3017-3023, 2003.

Mager DE, Mascelli MA, Kleiman NS, **Fitzgerald DJ**, Abernethy DR. Simultaneous modeling of abiciximab plasma concentrations and *ex vivo* pharmacodynamics in patients undergoing coronary angioplasty. ***J. Pharmacol. Exp. Ther.*** 307(3): 969-76, 2003.

Toomey S, Roche H, **Fitzgerald D**, Belton O. Regression of pre-established atherosclerosis in the apoE<sup>-/-</sup> mouse by conjugated linoleic acid. ***Biochem. Soc. Trans.*** 31(5): 1075-1079, 2003.

Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, **Fitzgerald D**, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT; Blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion. ***Circulation*** 108(4): 399-406, 2003.

Sheehan KM, Cahill RA, McGreal G, Steele C, Byrne MF, Kirwan WO, Kay EW, **Fitzgerald DJ**, Redmond HP, Murray FE. Cyclooxygenase-2 expression in primary human colorectal cancers and bone marrow micrometastases. ***Dig Liver Dis*** 36(6): 392-7, 2004

McCrorry C, **Fitzgerald DJ**. Spinal prostaglandin formation and pain perception following thoracotomy: a role for cyclooxygenase-2. ***Chest*** 125(4): 1321-7, 2004

Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, **Fitzgerald DJ**, Maguire PG. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. ***Blood*** 103(6): 2096-2104, 2004.

- McRedmond JP, Park SD, Reilly DF, Coppinger JA, Maguire PB, Shields DC, **Fitzgerald DJ**. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. ***Molec. Cellular. Proteomics*** 3(2): 133-144, 2004.
- Morgan MP, Whelan LC, Sallis JD, McCarthy CJ, **Fitzgerald DJ**, McCarthy GM. Basic calcium phosphate crystal-induced prostaglandin E2 production in human fibroblasts: role of cyclooxygenase-1 & -2 and interleukin-1b. ***Arthritis & Rheumatism*** 50(5): 1642-9, 2004.
- Kearney D, Byrne A, Crean P, Cox D, **Fitzgerald DJ**. Optimal suppression of thromboxane A2 formation by aspirin during percutaneous transluminal coronary angioplasty: No additional effect of a selective cyclooxygenase-2 inhibitor. ***J Am. Col. Cardiol*** 43(4): 526-531. 2004.
- Urquidi-Macdonald M, Mager DE, Mascelli MA, Frederick B, Freedman J, **Fitzgerald. DJ**, Kleiman NS, Abernethy DR. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. ***Clin Pharmacol Ther*** 75(1): 60-9. 2004.
- Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O, Bradford A, **Fitzgerald DJ**. Intravascular Thrombosis after hypoxia-induced pulmonary hypertension. Regulation by cyclooxygenase-2. ***Circulation*** 110(17):2701-2707, 2004.
- Byrne CE, Fitzgerald A, Cannon CP, **Fitzgerald DJ**, Shields DC. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. ***BMC Med Genet***. 5(1): 5-13, 2004.
- Reilly D, Larkin D, Devocelle M, **Fitzgerald DJ**, Moran N. Calreticulin-independent regulation of the platelet integrin alphaIIb beta3 by the KVGFFKR alphaIIb-cytoplasmic motif. ***Platelets*** 15(1):43-54, 2004.
- Murphy JF, Lennon F, Steele C, Kelleher D, **Fitzgerald D**, Long AC. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells. ***FASEB J***. 19(3): 446-448, 2005.

- . Kelly P, Maguire PB, Bennett M, Fitzgerald DJ, Edwards RJ, Thiede B, Treumann A, Collins JK, O'Sullivan GC, Shanahan F, Dunne C. Correlation of probiotic *Lactobacillus salivarius* growth phase with its cell wall-associated proteome. *FEMS Microbiol Lett.* 1;252(1):153-9, 2005.
- Lee J, Chubb AJ, Moman E, McLoughlin BM, Sharkey CT, Kelly JG, Nolan KB, Devocelle M, **Fitzgerald DJ**. Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H(2) synthase peroxidase activity. *Org Biomol Chem* 3(20): 3678-85. 2005.
- Mager DE, Shirey JD, Cox D, **Fitzgerald DJ**, Abernethy DR. Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network. *J Pharm Sci.* 94(11): 2475-86. 2005
- Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, **Fitzgerald DJ**. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. *J Am Coll Cardiol.* 46(7): 1258-1263, 2005.
- Toomey S, Harhen B, Roche HM, **Fitzgerald D**, Belton O. Profound resolution of early atherosclerosis with conjugated linoleic acid. *Atherosclerosis* 187(1): 40-9, 2006.
- McRedmond JP, Mulvihill NT, Kane M, Burke B, Aloul B, Forde T, Walsh M, **Fitzgerald DJ**. A rapid agglutination assay to detect anti-streptokinase antibodies. *Ir J Med Sci* 173(4): 204-210, 2004.
- Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, Crean P, Shields DC, **Fitzgerald DJ**. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. *J Thromb Haemost* 3(10): 2340-5, 2005.
- Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, **Fitzgerald DJ**. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. *J Am Coll Cardiol* 46(7): 1258-63, 2005.



Ahrens IG, Moran N, Aylward K, Meade G, Moser M, Assefa D, **Fitzgerald DJ**, Bode C, Peter K. Evidence for a differential functional regulation of the two beta(3)-integrins alpha(V)beta(3) and alpha(IIb)beta(3). *Exp Cell Res*. 312(6): 925-937, 2006.

O'Halloran AM, Curtin R, O'Connor F, Dooley M, Fitzgerald A, O'Brien JK, **Fitzgerald DJ**, Shields DC. The impact of genetic variation in the region of the GPIIIa gene, on PI expression bias and GPIIb/IIIa receptor density in platelets. *Br J Haematol*. 132(4):494-502, 2006.

Chubb AJ, **Fitzgerald DJ**, Nolan KB, Moman E. The productive conformation of prostaglandin G2 at the peroxidase site of prostaglandin endoperoxide H synthase: docking, molecular dynamics, and site-directed mutagenesis studies. *Biochemistry* 45(3): 811-820, 2006.

Neilan TG, Doherty GA, Chen G, Deflandre C, McAllister H, Butler RK, McClelland SE, Kay E, Ballou LR, **Fitzgerald DJ**. Disruption of COX-2 Modulates Gene Expression and the Cardiac Injury Response to Doxorubicin. *Am J Physiol Heart Circ Physiol*. 291(2): H532-6, 2006.

Cryan LM, Pidgeon GP, **Fitzgerald DJ**, O'Brien CJ. COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy. *Mol Vis* 12: 405-14. 2006.

Perneby C, Wallen NH, Rooney C, **Fitzgerald D**, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. *Thromb Haemost*. 95(4): 652-8, 2006.

Moore N, Dicker P, O'Brien JK, Stojanovic M, Conroy RM, Treumann A, O'Brien ET, Fitzgerald D, Shields D, Stanton AV. Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition. *Hypertension* 50(2): 340-7, 2007.

Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. *Circulation* 115(16): 2196-207, 2007.

Moore N, Dicker P, O'Brien JK, Stojanovic M, Conroy RM, Treumann A, O'Brien ET, **Fitzgerald D**, Shields D, Stanton AV. Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition. *Hypertension* 50(2): 340-7, 2007.

Corcoran PA, Atherton JC, Kerrigan SW, Wadstrom T, Murray FE, Peek RM, **Fitzgerald DJ**, Cox DM, Byrne MF. The effect of different strains of *Helicobacter pylori* on platelet aggregation. *Can J Gastroenterol* 21(6): 367-70, 2007.

Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB, **Fitzgerald DJ**, Cagney G. Moderation of the platelet releasate response by aspirin. *Blood*. 109 (11): 4786-92, 2007.

Coppinger J, **Fitzgerald DJ**, Maguire PB. Isolation of the platelet releasate. *Methods Mol Biol* 357:307-11, 2007.

Rajakariar R, Lawrence T, Bystrom J, Hilliard M, Colville-Nash P, Bellingan G, **Fitzgerald D**, Yaqoob MM, Gilroy DW. Novel biphasic role for lymphocytes revealed during resolving inflammation. *Blood*. 111(8):4184-92, 2008.

Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, Fitzgerald D, Yaqoob MM, Gilroy DW. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. *Proc Natl Acad Sci U S A*. 104(52): 20979-84, 2007.

Harney DF, Dooley M, Harhen B, McGuinness N, Cagney G, McCrory C, **Fitzgerald DJ**, Dowd NP. Nimesulide 90 mg orally twice daily does not influence postoperative morphine requirements after major chest surgery. *Anesth Analg* 106(1):294-300, 2008

Cryan LM, Paraoan L, Hiscott P, Damato BE, Grierson I, Gray D, Farrell M, Doherty GA, **Fitzgerald DJ**, O'Brien C. Expression of COX-2 and prognostic outcome in uveal melanoma. *Curr Eye Res*. 33(2):177-84, 2008.

Aronow HD, Califf RM, Harrington RA, Vallee M, Graffagnino C, Shuaib A, **Fitzgerald DJ**, Easton JD, Van de Werf F, Diener HC, Ferguson J, Koudstaal PJ, Amarenco P, Theroux P, Davis S, Topol EJ. Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). *Am J Cardiol*. 102(10):1285-90, 2008.

- Cathcart MC, Tamosiuniene R, Chen G, Neilan TG, Bradford A, O'Byrne KJ, **Fitzgerald DJ**, Pidgeon GP. Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. ***J Pharmacol Exp Ther.*** 326 (1):51-8, 2008.
- Cryan LM, **Fitzgerald DJ**, O'Brien C. Ocular prostaglandin production and morphology in mice lacking a single isoform of cyclooxygenase. ***Prostaglandins Leukot Essent Fatty Acids*** 81(5-6): 401-9, 2009.
- Doherty GA, Byrne SM, Molloy ES, Malhotra V, Austin SC, Kay EW, Murray FE, **Fitzgerald DJ** (2009) 'Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer'. ***BMC Cancer*** 9, 27-, 2009.
- Brennan LK, Harte BH, **Fitzgerald DJ**, McCrory CR. Surgery induces cyclooxygenase-2 expression in the rat cervical spinal cord. ***Reg Anesth Pain Med*** 34(6):549-52. 2009.
- McClelland S, Gawaz M, Kennerknecht E, Konrad CS, Sauer S, Schuerzinger K, Massberg S, **Fitzgerald DJ**, Belton O. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. ***Atherosclerosis*** 202 (1): 84-91, 2009.
- Doherty GA, Byrne SM, Austin SC, Scully GM, Sadlier DM, Neilan TG, Kay EW, Murray FE, **Fitzgerald DJ** Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer. ***Cancer*** 101 (3): 483-4, 2009.
- Steele BM, Harper MT, Macaulay IC, Morrell CN, Perez-Tamayo A, Foy M, Habas R, Poole AW, **Fitzgerald DJ**, Maguire PB. Canonical Wnt signaling negatively regulates platelet function'. ***Proceedings of the National Academy of Sciences of the United States of America*** 47: 19836-19841, 2009.
- Maree AO, Vangjeli C, Jneid H, Ryan J, Cox D, Cannon CP, Shields DC, **Fitzgerald DJ**. G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction(TIMI) 16 trial. ***J Thromb Haemost.*** 8(5): 934-41, 2010.

McClelland S, Cox C, O'Connor R, de Gaetano M, McCarthy C, Cryan L, **Fitzgerald D**, Belton O. Conjugated linoleic acid suppresses the migratory and inflammatory phenotype of the monocyte/macrophage cell. *Atherosclerosis* 211(1):96-102, 2010.

O'Connor R, Cryan LM, Wynne K, de Stefani A, **Fitzgerald D**, O'Brien C, Cagney G. Proteomics strategy for identifying candidate bioactive proteins in complex mixtures: application to the platelet releasate. *J Biomed Biotechnol.* 2010: 1-12, 2010.

Goodall AH, Burns P, Salles I, Macaulay IC, Jones CI, Ardissino D, de Bono B, Bray SL, Deckmyn H, Dudbridge F, **Fitzgerald DJ**, Garner SF, Gusnanto A, Koch K, Langford C, O'Connor MN, Rice CM, Stemple D, Stephens J, Trip MD, Zwaginga JJ, Samani NJ, Watkins NA, Maguire PB, Ouwehand WH; Bloodomics Consortium. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. *Blood* 116:4646-562010, 2010.

O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, **Fitzgerald DJ**, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD; on behalf of the LANCELOT Investigators. Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes: The Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial. *Circulation.* 123: 1843-53, 2011.

Wiviott SD, Flather MD, O'Donoghue ML, Goto S, **Fitzgerald DJ**, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL; on behalf of the LANCELOT Investigators. Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial. *Circulation.* 123: 1854-63, 2011.

Brian M. Steele, Matthew T. Harper, Albert P. Smolenski, Naheda Alkazemi, Alastair W. Poole, **Desmond J. Fitzgerald** and Patricia B. Maguire. WNT-3a modulates platelet function by regulating small GTPase activity. *FEBS Letters* 586: 2267-72, 2012.

Macaulay IC, Thon JN, Tijssen MR, Steele BM, Macdonald BT, Meade G, Burns P, Rendon A, Salunkhe V, Murphy RP, Bennett C, Watkins NA, He X, **Fitzgerald DJ**, Italiano JE Jr, Maguire PB. Canonical Wnt signaling in megakaryocytes regulates proplatelet formation. *Blood* 121: 188-96, 2013.

Steele BM, Harper MT, Smolenski AP, Alkazemi N, Poole AW, **Fitzgerald DJ**, Maguire PB. WNT-3a modulates platelet function by regulating small GTPase activity. ***FEBS Letters***; 586: 2267-72, 2012.

McCarthy C, Lieggi NT, Barry D, Mooney D, de Gaetano M, James WG, McClelland S, Barry MC, Escoubet-Lozach L, Li AC, Glass CK, **Fitzgerald DJ**, Belton O. Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid. ***EMBO Mol Med***. 5: 1443-57, 2013.

Marcone S, **Fitzgerald DJ**. Proteomic identification of the candidate target proteins of 15-deoxy-delta12,14-prostaglandin J<sub>2</sub>. ***Proteomics***. 13: 2135-9, 2013.

Macaulay IC, Thon JN, Tijssen MR, Steele BM, MacDonald BT, Meade G, Burns P, Rendon A, Salunkhe V, Murphy RP, Bennett C, Watkins NA, He X, **Fitzgerald DJ**, Italiano JE Jr, Maguire PB. Canonical Wnt signaling in megakaryocytes regulates proplatelet formation. ***Blood***. 121: 188-96, 2013.

McCarthy C, Duffy MM, Mooney D, James WG, Griffin MD, **Fitzgerald DJ**, Belton O. IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis. ***FASEB J***. 27: 499-510, 2013.

Barron AJ, Hughes AD, Sharp A, Baksi AJ, Surendran P, Jabbour RJ, Stanton A, Poulter N, **Fitzgerald D**, Sever P, O'Brien E, Thom S, Mayet J; ASCOT Investigators. Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. ***Hypertension***. 63: 252-8, 2014.

Marcone S, Haughton K, Simpson P, Belton O and **Fitzgerald DJ**. Milk-derived bioactive peptides inhibit human 3 endothelial-monocyte interactions via PPAR-γ 4 dependent regulation of NF-κB. ***J Inflammation*** 2015 12(1):1.

Marcone S, Evans P, **Fitzgerald DJ**. 15-Deoxy-Delta12,14-prostaglandin J<sub>2</sub> modifies components of the proteasome and inhibits inflammatory responses in human endothelial cells. ***Frontiers in Immunology*** (in press)



## CHAPTERS, BOOKS AND EDITORIALS

**Fitzgerald DJ**, O'Callaghan WG, O'Malley K, O'Brien ET. Assessment of the Remler M2,000 semiautomatic ambulatory blood pressure recorder. ***Proceedings of the 4<sup>th</sup> International Symposium on Ambulatory Monitoring and the 2<sup>nd</sup> Gent Workshop of Blood Pressure Variability***. Ed. Stott FD, Raftery EB, Clement DL, Wright SL. 484-489. Academic Press, London, 1982.

**Fitzgerald DJ**, O'Callaghan WG, O'Malley K, O'Brien ET. Accuracy of the London School of Hygiene and Remler M2,000 Sphygmomanometers. ***Clinical Science*** 61. Suppl. 7: 399s-401s, 1982.

**Fitzgerald DJ**, O'Malley K. Therapeutic agents available in Europe that have not been released in the United States. Chapter in "***Essentials of Pharmacology***", 3<sup>rd</sup> edition. Eds. Bevan JA, Thompson JH. Harper Row, Philadelphia, 1984, pp 837-859.

**Fitzgerald DJ**, O'Malley K, O'Brien ET. Clinical examination of the hypertensive patient including blood pressure measurement. In "***Hypertensive Cardiovascular Disease: Pathophysiology and Treatment***". Ed. Amery A, Fagard R, Lignen P, Stressen J. Chapter 41, 629-648. Martinus Nijkoff, the Hague, 1982.

**Fitzgerald DJ**, O'Brien ET, O'Malley K. Vasodilators in the management of hypertension. ***Proc. 8<sup>th</sup> Int. Congr. Nephrol.*** S11: 471-477, 1981.

**Fitzgerald DJ**, O'Callaghan WG, Horgan J, O'Brien ET, O'Malley K. Acute and long-term responses to captopril and hydralazine in congestive heart failure. The importance of preload reduction. ***Br. J. Clin. Pharmacol.*** 14: 217s-222s, 1982.

FitzGerald GA, **Fitzgerald DJ**. Thromboxane A<sub>2</sub> biosynthesis in renal disease (***Editorial***). ***JAMA***. 251:3121-3123, 1984.

O'Brien E, **Fitzgerald DJ**, and O'Malley, K.: Blood pressure measurement: Current practice and future trends. (***Editorial***) ***Br. Med. J.*** 290: 729-34, 1985.

**Fitzgerald DJ**, O'Malley K. Plasma drug levels as an aid to medical treatment. (*Editorial*) *Ir. Med. J.* 77: 23-6, 1985.

**Fitzgerald DJ**, FitzGerald GA. Antiplatelet and anticoagulant therapy during coronary thrombolysis. *Trends in Cardiovasc Med* 1: 29-35, 1990.

**Fitzgerald DJ**. Alprostadil. In: *Therapeutic Drugs*. Ed. Dollery C. Churchill Livingstone, Edinburgh, 1992.

**Fitzgerald DJ**. Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators. *Am J Cardiol* 68: 51B-57B, 1991.

FitzGerald GA, Price P, Rocki W, **Fitzgerald DJ**. Thromboxane A<sub>2</sub> in pregnancy-induced hypertension. In: *Issues in Nephrosciences*. Editors Wichtig J., pp. 3-7,1991.

Delanty N, **Fitzgerald DJ**. Heparin during coronary thrombolysis: too little, too late. (*Editorial*) *Circulation*, 86: 1636-1638, 1992.

**Fitzgerald DJ**, Smeed M. Management of mild to moderate hypertension. *Ir Med J* 86: 45-46, 1993.

**Fitzgerald DJ**. Specific thrombin inhibitors in vivo. *Annals of the New York Academy of Science* 1993, pp 41-51.

Reilly M, **Fitzgerald DJ**. Platelet activation during thrombolytic therapy in unstable angina. In: Glas-Greenwalt P, Ed. *Fibrinolysis in Disease*: CRC Press, Inc. Boca Raton, Chapter 21, 1995.

Keimowitz RM, **Fitzgerald DJ**. Warfarin and aspirin after heart valve replacement. *N Engl J Med* 228: 508, 1994.

**Fitzgerald DJ**. Adjunctive therapy in coronary thrombolysis: prostaglandins, nitrates and calcium antagonists. *Coronary Artery Disease* 6: 940-946, 1995.



**Fitzgerald DJ**, Moran N. Aspirin: the world's oldest prescription drug. *J Coll Phys & Surg* 24 (4): 279-282, 1995.

**Fitzgerald DJ**. Adjunctive therapy of coronary thrombolysis: prostaglandins, nitrates and calcium channel blockers. *Coronary Artery Disease* 6 (12): 940-946, 1995.

**Fitzgerald DJ**, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. *Coronary Artery Disease* 7: 455-458, 1996.

Delanty N, Reilly M, Pratico D, **Fitzgerald DJ**, Lawson JA, and FitzGerald GA, 8-Epi PGF<sub>2α</sub>: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. *Br. J. Clin Pharm*; 42: 15-19, 1996.

**Fitzgerald DJ**. Calcium Channel Blockers in the Management of Hypertension. *Irish Medical Journal* 89: 8, 1996.

Delanty N, **Fitzgerald DJ**. Paracetamol poisoning: the action line and the timing of acetylcysteine therapy. *Irish Medical Journal* 89: 156-158, 1996.

Forde RC, **Fitzgerald DJ**. Reactive oxygen species and platelet activation in reperfusion injury. *Circulation* 95: 787-789, 1997.

Kelly L, **Fitzgerald DJ**. The management of hypercholesterolaemia. *Irish Medical Journal* 91:1, 1997.

Kelly L, Forde RC, **Fitzgerald DJ**. Thrombosis in the pathogenesis of coronary artery disease. *J Coll. Phy. Surg.* 26: 125-127, 1997.

Quinn M, **Fitzgerald DJ**. Long-term administration of glycoprotein IIb/IIIa antagonists. *Am. Heart J.* 135: 113-114, 1998.

Reilly M, **Fitzgerald DJ**. Thrombosis in the pathogenesis of coronary artery disease. In: **Unstable Coronary Artery Syndromes**: pathophysiology, diagnosis & treatment. Wilensky RL (ed). Kluwer Academic Publishers, pp 59-86, 1998.

Regan CL, **Fitzgerald DJ**. Aspirin and prostanoids in pre-eclampsia. **Handbook of Hypertension**. 1999.

Kearney D, **Fitzgerald DJ**. The anti-thrombotic effects of statins. (**Editorial**) **J Am Coll Cardiol** 33 (5): 1305-1307, 1999

Quinn M, **Fitzgerald DJ**. Clopidogrel and ticlopidine: inhibitors of platelet ADP receptors. (**Editorial**) **Circulation** 100: 1667-1672, 1999.

**Fitzgerald DJ**. Fibrinogen receptor and platelet signalling. **Blood Coagulation and Fibrinolysis**. 10 (Suppl 1): S77-S79, 1999.

Quinn M, **Fitzgerald DJ**. Overview of antiplatelet agents. In: **Antiplatelet Therapy in Clinical Practice**. Eds. Ferguson J, Chronos JA, Harrington RA. Martin Dunitz Publishers, pp 69-83, 2000.

Curtin R, **Fitzgerald DJ**. A cold start for oral glycoprotein IIb/IIIa antagonists. **Eur Heart J** 21: 1992-1994, 2000.

Curtin R, Cox D, **Fitzgerald DJ**. Clopidogrel and Ticlopidine. In: **The platelets**. Eds. Michelson AD. Academic Press, San Diego. 2002; pp 787-801.

McRedmond JP, **Fitzgerald DJ**. A growing set of platelet-activating bacterial proteins. **Blood** 99: 1, 2001.

**Fitzgerald DJ**. Vascular biology of thrombosis: the role of platelet vessel wall adhesion. **Neurology**; 57 (Suppl 2): S1-4, 2001.

**Fitzgerald DJ, Cox D.** Monitoring antiplatelet therapy. In: **Platelets in Thrombotic and Non-Thrombotic Disorders**. Ed. Gresele P. Cambridge University Press 2002; pp 471-484

Maguire P and **Fitzgerald DJ.** Platelet proteomics. **J Thromb Haemost.** 1(7): 1593-601, 2003

Maree A, **Fitzgerald DJ.** PAR2 is *Partout* and Now in the Heart. **Circulation Research** 90: 366-368, 2003

McRedmond JP, **Fitzgerald DJ.** A partial CURE for acute coronary syndromes – but how did it happen? **Eur. Heart J** 23: 1730-1732, 2002

Belton O, **Fitzgerald DJ.** COX-2 inhibitors and atherosclerosis. **J. Am. Coll. Cardiol** 41 (10): 1812-1819, 2003

Curtin R, **Fitzgerald DJ.** Pharmacogenetics of antiplatelet drugs. **The Scientific World** 2: 791-800, 2002

Belton O, **Fitzgerald DJ.** Cyclooxygenase isoforms and atherosclerosis. **Expert Reviews in Molec. Med** 5: 1-18, 2003.

Maree A, **Fitzgerald DJ.** Glycoprotein IIb/IIIa antagonists in acute coronary syndromes. **Haematologica** 86: 45-48, 2001.

Maree A, **Fitzgerald DJ.** Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now? **Seminars in Cardiovasc. Med** 3(4) 385-390, 2003

Belton O, **Fitzgerald DJ.** Coxlooxygenase-2 inhibitors and atherosclerosis. **J. Am. Coll. Cardiol** 41(10): 1820-23, 2003

Maree AO, **Fitzgerald DJ.** Aspirin and coronary artery disease. **Thromb Haemost** 92(6):1175-81, 2004.

Maguire PB, Moran N, Cagney G, **Fitzgerald DJ**. Application of proteomics to the study of platelet regulatory mechanisms. ***Trends in Cardiovascular Medicine*** 14(6):207-20, 2004.

McCrorry C, **Fitzgerald D**. Spinal prostaglandin formation and pain perception following thoracotomy: a role for cyclooxygenase-2. ***Chest***. 125(4): 1321-7, 2004.

Iohom G, **Fitzgerald D**, Cunningham AJ. Principles of pharmacogenetics--implications for the anaesthetist. ***Br J Anaesth*** 93(3):440-50. Review. 2004.

Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, **Fitzgerald D**, Hirsh J, Husted S, Kvasnicka J, Montalescot G, García Rodríguez LA, Verheugt F, Vermynen J, Wallentin L, Priori SG, Alonso Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernández Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Morais J, Deckers J, Ferreira R, Mazzotta G, Steg PG, Teixeira F, Wilcox R; European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. ***Eur Heart J*** 25(2):166-81. Review. 2004.

Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, **Fitzgerald D**, Hirsh J, Husted S, Kvasnicka J, Montalescot G, García Rodríguez LA, Verheugt F, Vermynen J, Wallentin L; Grupo de Trabajo sobre el uso de agentes antiplaquetarios en pacientes con enfermedad cardiovascular aterosclerótica de la Sociedad Europea de Cardiología. [Expert consensus document on the use of antiplatelet agents]. ***Rev Esp Cardiol*** 57(10):963-80. Review. 2004

Maguire PB, Moran N, Cagney G, **Fitzgerald DJ**. Application of proteomics to the study of platelet regulatory mechanisms. ***Trends Cardiovasc Med***. 14(6): 207-20. Review. 2004.

Maguire PB, Foy M, **Fitzgerald DJ**. Using proteomics to identify potential therapeutic targets in platelets. ***Biochem Soc Trans*** 33(Pt 2): 409-12, 2005.

Watson SP, Bahou WF, **Fitzgerald D**, Ouwehand W, Rao AK, Leavitt AD; ISTH Platelet Physiology Subcommittee. Mapping the platelet proteome: a report of the ISTH Platelet Physiology Subcommittee. ***J Thromb Haemost*** 3(9): 2098-101, 2005

Macaulay IC, Carr P, Gusnanto A, Ouwehand WH, **Fitzgerald D**, Watkins NA. Platelet genomics and proteomics in human health and disease. ***J Clin Invest*** 115(12): 3370-7, 2005

Platelet Function: Assessment, Diagnosis, and Treatment, Quinn M, **Fitzgerald D** editors. Springer 2005.

Maree AO, Jneid H, **Fitzgerald DJ**. Aspirin resistance and atherothrombotic disease. ***J Am Coll Cardiol***. 15;48(4):846-7, 2006; author reply 847.

**Fitzgerald DJ**, Maree A. Aspirin and clopidogrel resistance. ***Hematology Am Soc Hematol Educ Program*** 114-20, 2007

Maree AO, **Fitzgerald DJ**. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. ***Circulation*** 24; 115(16):2196-207, 2007.

Maree AO, Cox D, **Fitzgerald DJ**. Drug insight: aspirin resistance-fact or fashion? ***Nat Clin Pract Cardiovasc Med*** 4(3): E1; 2007.

Maree AO, Jneid H, Palacios IF, Rosenfield K, MacRae CA, **Fitzgerald DJ**. Growth arrest specific gene (GAS) 6 modulates platelet thrombus formation and vascular wall homeostasis and represents an attractive drug target. ***Curr Pharm Des*** 13(26): 2656-61. 2007.

**Fitzgerald DJ**, Fitzgerald GA. Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. ***Circ Res***. 112:174-94, 2013.

Marcone S, Dervin F and **Fitzgerald DJ**. Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects. ***J Thromb Haemostasis*** 13 Suppl 1:S323-31. 2015.

Marcone S, Belton O and **Fitzgerald DJ**. Milk-derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis ***BJCP*** (In Press).